In a glioma model, we have shown that administration of VSV encoding tumor antigens c-Myc, HIF-2α, and Sox-10 in combination with anti-PD-1 therapy or anti-CTLA-4 was able to prolong the survival of mice bearing intra-cranial tumors. This evidence concerns the gene CTLA4 and neoplasm.